CN-122005617-A - Application of active ruminococcus in preparing medicament for preventing or treating children obesity related cognitive dysfunction

Abstract

The invention belongs to the technical field of biological medicine, and provides application of active ruminococcus in preparing a medicament for preventing or treating cognitive disorder related to childhood obesity, aiming at the problem that a biological mechanism related to childhood obesity and cognitive disorder is still unknown at present. Active ruminococcus can inhibit microglial activation and reduce neuroinflammation by metabolizing D-pipecolic acid, thereby preventing or treating cognitive disorder related to childhood obesity. According to experimental research, the invention discovers that the fixed planting of active ruminococcus in a mouse model can reverse obesity-induced cognitive dysfunction, inhibit activation of microglial cells in brain and reduce neuroinflammation, so that the active ruminococcus has the treatment potential of reducing the obesity-related cognitive dysfunction of children.

Inventors

• Zhang Jianduan
• WANG MIYUAN
• XU KE
• LIU RONG
• ZHANG HUILIANG
• DONG WENLI
• XIA WENQI
• ZHANG YUANYUAN
• WANG YIMIN
• JIANG YANFEN

Assignees

• 华中科技大学

Dates

Publication Date

20260512

Application Date

20260225

Claims (6)

1. 1. Use of active ruminococcus in the manufacture of a medicament for preventing or treating childhood obesity-related cognitive disorders.
2. 2. The use according to claim 1, wherein the active ruminococcus inhibits microglial activation and reduces neuroinflammation by metabolizing D-pipecolic acid, enabling prevention or treatment of childhood obesity-related cognitive disorders.
3. 3. A medicament for preventing or treating cognitive impairment associated with obesity in children, comprising active ruminococcus.
4. 4. A medicament for preventing or treating childhood obesity-related cognitive disorders as in claim 3, wherein the active ruminococcus inhibits microglial activation and reduces neuroinflammation by metabolizing D-pipecolic acid, effecting prevention or treatment of childhood obesity-related cognitive disorders.
5. 5. A medicament for the prevention or treatment of childhood obesity-related cognitive disorders as in claim 3, further comprising a pharmaceutically acceptable adjuvant.
6. 6. The medicament according to claim 5, wherein the excipients comprise one or more of lactose, maltose, microcrystalline cellulose, carboxymethyl cellulose, polyvinylpyrrolidone, hydroxypropyl methylcellulose, polymethyl methacrylate, starch, sucrose, glucose, aspartame, water, ethanol, glycerol, benzoic acid, formic acid, sodium benzoate.

Description

Application of active ruminococcus in preparing medicament for preventing or treating children obesity related cognitive dysfunction Technical Field The invention belongs to the technical field of biological medicines, and particularly relates to application of active ruminococcus in preparing a medicament for preventing or treating cognitive impairment related to childhood obesity. Background Childhood obesity is an urgent global public health challenge, and its prevalence has increased significantly over the last decades. Importantly, early life obesity is associated with impaired brain development and cognitive dysfunction. Obese children perform poorly in a number of cognitive areas (especially suppression of control and memory), which can negatively impact academic performance and long-term human growth. However, the biological mechanisms associated between childhood obesity and cognitive disorders are still unclear. More and more studies have shown that there is a significant imbalance in intestinal flora in obese children. There is strong evidence supporting that the intestinal flora and its metabolites play a key role in regulating cognitive processes. For example, alterations in specific intestinal flora (e.g. lactobacillus) and metabolites (e.g. mannose) are associated with late cognitive outcome in children early in life. Thus, intestinal flora and metabolic disorders thereof may lead to cognitive decline associated with obesity during development. However, the integrated pathway linking obesity, gut flora, metabolites and cognition is only partially established and the main evidence comes from adults. For example, previous studies in adults have found that obesity-related microbial functions and metabolite alterations (such as those involved in the one-carbon metabolism, histidine and tryptophan pathways) are associated with inhibition control and memory deficits. In contrast, preschool is a key stage of cognitive development, the prevalence rate of obesity rises rapidly at this time and obesity-related cognitive disorders appear, and excessive obesity appearing at this time may significantly obstruct infant development trails, but related studies on infants are obviously lacking at present, and intestinal flora in childhood is still in the maturation process, and the diversity and composition of intestinal flora in childhood are significantly different from those of adults, so that the results of adult studies cannot be directly applied to childhood. Disclosure of Invention The invention provides application of active ruminococcus to preparation of a medicament for preventing or treating cognitive impairment related to childhood obesity, and aims to solve the problem that whether correlation is unclear between intestinal flora and cognitive impairment related to childhood obesity exists at present. In order to achieve the above purpose, the invention adopts the following technical scheme: in one aspect, the invention provides the use of ruminococcus liveness in the manufacture of a medicament for the prevention or treatment of cognitive impairment associated with childhood obesity. Preferably, the active ruminococcus inhibits microglial activation and reduces neuroinflammation by metabolizing D-pipecolic acid, thereby realizing the prevention or treatment of childhood obesity-related cognitive disorders. In another aspect, the invention provides a medicament for preventing or treating cognitive impairment associated with childhood obesity comprising ruminococcus livens. Preferably, the active ruminococcus inhibits microglial activation and reduces neuroinflammation by metabolizing D-pipecolic acid, thereby realizing the prevention or treatment of childhood obesity-related cognitive disorders. Preferably, the medicament further comprises pharmaceutically acceptable auxiliary materials. Preferably, the auxiliary materials comprise one or more of lactose, maltose, microcrystalline cellulose, carboxymethyl cellulose, polyvinylpyrrolidone, hydroxypropyl methylcellulose, polymethyl methacrylate, starch, sucrose, glucose, aspartame, water, ethanol, glycerin, benzoic acid, formic acid and sodium benzoate. Compared with the prior art, the invention has the beneficial effects that: The present invention discovers a novel gut-brain axis that relates to ruminococcus livens and D-pipecolic acid (dppi) in childhood obesity, which relates childhood flora changes to cognitive dysfunction. According to experimental research, the invention discovers that active ruminococcus colonization can reverse obesity-induced cognitive dysfunction, inhibit activation of mouse microglial cells and reduce neuroinflammation. The above findings of the present invention support restoration of active ruminococcus abundance and reduction of dppi levels as a microbial targeting strategy, and this strategy has therapeutic potential for the reduction of childhood obesity-related cognitive disorders. Drawings FIG. 1 shows the results